# Junta clínica — PT-pseudo_ac05cda1a88a (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_ac05cda1a88a",
  "pid": "PT-pseudo_ac05cda1a88a",
  "task": 1,
  "psa": 14.5,
  "age": 44,
  "months": 3,
  "pirads": "5",
  "psad": 0.29,
  "psav": 6.16,
  "psap": 11.4,
  "vol": 51.0,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.89338696,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 14.5 ng/mL. PI-RADS 5. PSAD 0.29. Prostate volume 51 mL. DRE nodus. csPCa 0.89.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "67 kg",
    "height": "172 cm",
    "bmi": "22.6",
    "bp": "125/69 mmHg",
    "hr": "67 bpm",
    "smoking": "Non-smoker",
    "last_dental": "2 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "17 Jan 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent PSA elevation combined with a previously confirmed low-grade prostate malignancy prompted this clinical evaluation."
    },
    {
      "s": "History",
      "t": "A 44-year-old retired farmer seeks re-evaluation for a previously confirmed prostate malignancy and subsequent PSA increase. Marital status is divorced, though he currently resides with his partner, and his adult daughter acts as his main contact. Lower urinary tract symptoms reach an IPSS score of 15, chiefly due to nocturia and a diminished stream, while haematuria and pelvic discomfort are absent. Physical activity remains limited to occasional walking within a largely sedentary routine, alongside a weekly alcohol intake of roughly 15 units. Surgical history is minimal, featuring only a minor arthroscopic knee intervention during his thirties. He maintains a non-smoking status and carries a BMI of 22.6. Each clinic attendance demands a train journey exceeding one hour, necessitating extended consultation time."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals a firm, discrete nodule situated in the right mid-gland peripheral zone, while the remaining prostatic tissue feels symmetric and smooth. Vital parameters remain within normal limits, recording a blood pressure of 125/69 mmHg and a pulse of 67 bpm. The broader physical assessment shows no abdominal masses or palpable lymph node enlargement."
    }
  ],
  "occupation": "retired farmer",
  "marital": "Divorced",
  "living": "Lives with partner",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Sleep clinic — suspected obstructive sleep apnoea"
  ],
  "alcohol": "15 units / week",
  "exercise": "Sedentary lifestyle, occasional walking",
  "ipss": "IPSS score: 15/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Radboudumc",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_ac05cda1a88a
Task: 1

Encounter: Urology - outpatient on 17 Jan 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 44-year-old male
  - PSA: 14.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.29 ng/mL²
  - PSA velocity: 6.16 ng/mL/yr
  - Prior PSA: 11.4 ng/mL
  - Prostate volume: 51.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.89338696 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 14.5 ng/mL. PI-RADS 5. PSAD 0.29. Prostate volume 51 mL. DRE nodus. csPCa 0.89.

Vitals: weight 67 kg, height 172 cm, BMI 22.6, BP 125/69 mmHg, HR 67 bpm. Smoking: Non-smoker.

Chief complaint: Persistent PSA elevation combined with a previously confirmed low-grade prostate malignancy prompted this clinical evaluation.

History: A 44-year-old retired farmer seeks re-evaluation for a previously confirmed prostate malignancy and subsequent PSA increase. Marital status is divorced, though he currently resides with his partner, and his adult daughter acts as his main contact. Lower urinary tract symptoms reach an IPSS score of 15, chiefly due to nocturia and a diminished stream, while haematuria and pelvic discomfort are absent. Physical activity remains limited to occasional walking within a largely sedentary routine, alongside a weekly alcohol intake of roughly 15 units. Surgical history is minimal, featuring only a minor arthroscopic knee intervention during his thirties. He maintains a non-smoking status and carries a BMI of 22.6. Each clinic attendance demands a train journey exceeding one hour, necessitating extended consultation time.

Physical examination: DRE reveals a firm, discrete nodule situated in the right mid-gland peripheral zone, while the remaining prostatic tissue feels symmetric and smooth. Vital parameters remain within normal limits, recording a blood pressure of 125/69 mmHg and a pulse of 67 bpm. The broader physical assessment shows no abdominal masses or palpable lymph node enlargement.

Patient info: retired farmer; Divorced; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 15 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Sleep clinic — suspected obstructive sleep apnoea.
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.51
  uncertainty  +/- 0.11 epistemic (95% band 0.30-0.72); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 2.38: PI-RADS 5, PSA 8.7, PSAD 0.4, age 54, DRE Normal -> BIOPSY (uncertain). He wrote: "Young patient with high risk disease, should be recommended curative treatment. Biopsy report congruent with MRI, probably caught the index cancer at diagnosis. Highrisk…"
  2. distance 2.43: PI-RADS 5, PSA 4.53, PSAD 0.12, age 50, DRE Normal -> BIOPSY (clear). He wrote: "young patient with pirads5= high probability of significant prostate cancer and only one prev biopsy, increasing PSA. indicated with one more confirmatory biopsy to excl…"
  3. distance 2.46: PI-RADS 5, PSA 10.92, PSAD 0.26, age 61, DRE Nodus -> DEFER (clear). He wrote: "Advocate for curative treatment while unfavorable intermediate risk pc in young patient without significant comorbidity. IF he is cautious toward curative treatment, rep…"

PRECEDENT: BIOPSY (weighted vote 0.67 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=decisive, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the need for repeat biopsy following a prior positive biopsy, focusing on MRI findings and PSA density. "sion on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy." It also notes that "Patients with stable results (PRECISE 3) on repeat MRI during AS combined with a low PSA-D (< 0.15) have a very low rate of progression and may be a group in whom standard repeat biopsy may be omitted."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not settled because the guideline makes the decision dependent on MRI findings and PSA density, which are not fully established here. The precedent cited by Expert 5 shows that the reading urologist's decision varied based on the specific PI-RADS score and PSA level, which is a variable that Expert 1's general rule does not account for.

WHAT WE STILL NEED
The panel already contains the following known facts:
*   PSA: 14.5 ng/mL (This is above the threshold of 10 ng/mL mentioned in one search result).
*   PI-RADS: 5 (This is a high-risk finding that the guideline suggests should prompt further investigation).
*   Prior-biopsy status: Positive (This is the key factor that the guideline requires further context on).
*   PSA density: 0.29 ng/mL² (This value is above the threshold of 0.15 mentioned in the guideline).
*   Months since last PSA: 3 (This is a short interval, which is relevant to surveillance frequency).

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the grade and surveillance status from the previous notes to determine the next step.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy grade (Gleason/ISUP), surveillance protocol status, number of biopsy sessions, and planned treatment?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason or ISUP) and surveillance status from the previous notes?
  Q2. Does the mpMRI prose indicate any findings that mandate a repeat biopsy according to the EAU guideline?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone is a "4 mm hypointense focus" in the "right mid-gland peripheral zone". Extraprostatic extension is not explicitly mentioned. Comparison against an earlier study is "new" as the report is dated "10 January 2025".
psa_trend
The serial PSA value trend is "rising", with values: "Nov 2022: 2.4 ng/mL", "Dec 2023: 5.9 ng/mL", "Jan 2025: 14.5 ng/mL".
previous_notes
The management context includes the prior biopsy grade as "Positive" (implied by the context of re-evaluation for a confirmed malignancy), surveillance protocol status as "not recorded", number of biopsy sessions as "not recorded", and planned treatment as "not recorded".

WHAT I DID NOT OPEN
family-history anamnesis, as it was not requested by the moderator and is not critical for the immediate decision based on the opened documents.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS score of "5" from the mpMRI report.
PSA density of "0.29 ng/mL/mL".

Findings that argue AGAINST sampling this patient now:
Prior biopsy status is "Positive".
Surveillance protocol status is "not recorded".

WHERE THIS LEANS
The findings strongly suggest further investigation is warranted due to the high PI-RADS score and elevated PSA density.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 14.50 ng/mL over 3 points spanning 26 months; velocity +5.58 ng/mL per year; doubling time about 10 months.
PROJECTION at 6 months: 24.5 ng/mL, conformal 95% band 7.0-85.2.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.08 epistemic (95% band 0.47-0.79), of which 0.01 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.51  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.63  ('supports' tier, fusion_nolab)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.67  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.61 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_nolab). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=decisive, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened—radiology_report, psa_trend, and previous_notes—address the moderator's questions to some extent. The registrar retrieved the rising PSA trend and noted that the prior biopsy grade and surveillance status were "not recorded" in the previous notes.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a BIOPSY based on a weighted vote, noting that the documented prior grade was "none recorded." The retrieved information confirms the lack of documented grade and surveillance status, which aligns with the panel's reliance on the trained experts' vote.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason or ISUP) and surveillance status from the previous notes? This question remains unanswered, as the previous_notes explicitly state this information is "not recorded."
Q2. Does the mpMRI prose indicate any findings that mandate a repeat biopsy according to the EAU guideline? The EAU guideline was reviewed, and the fusion expert noted that the PI-RADS 5 and PSA density of 0.29 ng/mL² suggest further investigation, but the specific prose mandating a repeat biopsy is not explicitly confirmed by the retrieved documents.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 5 and the PSA density of 0.29 ng/mL² carry significant weight because they are high-risk findings that the EAU guideline suggests should prompt further investigation. However, the lack of documented prior biopsy grade and surveillance status is a critical missing piece that prevents a definitive decision based on established protocols.

MY SUGGESTION TO THE CHAIR
Given that the key variables required by the panel protocol—specifically the prior biopsy grade and surveillance status—are missing from the retrieved documents, the decision cannot be definitively made according to the protocol. Therefore, the case is not ready for a final decision based on the retrieved evidence alone.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the high PI-RADS score of 5 and the rising PSA trend, coupled with the DRE finding of a nodule, further investigation is warranted despite the prior positive biopsy status being undocumented. The combination of these high-risk imaging and biochemical findings, as noted in the retrieved reports, strongly supports proceeding with a repeat biopsy to establish the current pathological status.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
